Premature ventricular contraction, ofatumumab, chronic lymphocytic leukemia
Ofatumumab is a monoclonal antibody used in the treatment of recurrent and progressive chronic lymphocytic leukaemia (CLL) and was recently approved for the treatment of multiple sclerosis.
We describe the case of a 68-year-old man who presented with complaints of irregular pulse readings while undergoing ofatumumab treatment for recurrent CLL. Electrocardiograms (ECGs) demonstrated premature ventricular contractions (PVCs) which eventually caused cardiomyopathy and failed to resolve despite ablative therapy. Ofatumumab-induced PVCs are confirmed in this case by the existence of documented PVCs on ECGs and the disappearance of these PVCs after the completion of ofatumumab treatment.
To the best of our knowledge, there have been no previously reported cases of PVCs associated with ofatumumab in the literature.
HTML downloads: 53
PDF downloads: 207
Issue: 2022: Vol 9 No 11 (view)